

Transparency Reporting at Kyowa Kirin
Methodological Note for 2021 data

1. Introduction

Kyowa Kirin Ltd and Kyowa Kirin International are committed to supporting healthcare and the development of patient care across the UK and Ireland. We are pleased to do this through providing funds to Healthcare Organisations (HCOs) or Healthcare Practitioners (HCPs) and through engaging them for services that contribute to the improvement of patient care. In accordance with ABPI & IPHA Code requirements, Kyowa Kirin Ltd and Kyowa Kirin International publish details about transfers of value to these individuals and organisations on an annual basis.

Each Kyowa Kirin affiliate in Europe is accountable for capturing and validating data in their nation and we make one disclosure per market. This disclosure covers transfers of value between 1st January 2021 to 31st December 2021 to HCPs and HCOs which are registered in the UK and Ireland.

2. Scope of disclosure

This disclosure includes the following transfers of value:

EFPIA Category	EFPIA sub-category	Example activities (not exhaustive)
Donations and grants	N/A	<ul style="list-style-type: none"> • Donations to HCOs • Educational grants • Investigation Sponsored Studies
Contribution to cost of events	Sponsorship agreements	<ul style="list-style-type: none"> • Sponsorship of congresses organised by HCOs or third-parties on their behalf
	Registration fees	<ul style="list-style-type: none"> • Funding of HCPs to attend congresses
	Travel and accommodation	<ul style="list-style-type: none"> • HCP's travel and accommodation costs for attending congresses
	Subsistence	<ul style="list-style-type: none"> • Cost of subsistence (from July 1st)

Fees for service	Fees	Fees for: <ul style="list-style-type: none"> • Chairing or attending Advisory Boards • Speaking engagements • Medical writing
	Related expenses	Travel and accommodation expenses relating to the activities above
Research and Development	N/A	Activities relating to: <ul style="list-style-type: none"> • planning or conduct of clinical studies • clinical trials • non-interventional studies that are prospective in nature • clinical investigator meetings

If activities relate to retrospective non-interventional studies, then they are included in Fees for Service, rather than Research and Development.

This disclosure excludes the following transfers of value:

- Logistical costs related to KKI-organised meetings (e.g., room hire)

As the ABPI and IPHA Codes of Practice requirements for 2021 only relates to transfers of value to HCPs and HCOs, this disclosure does not include:

- Donations to non-HCOs
- Support provided to Patient Organisations. This is disclosed in a separate report.

Some HCPs continue to provide advice to the healthcare community after they have retired. Generally, KKI include such HCPs in the applicable regulation's definition of an HCP, however this depends on their role and ability to prescribe and influence.



3. Date of Transfers of Value

The date of the transfers of value included in this disclosure is based on date of payment (where the transfer of value is a payment).

If the transfer of value is a benefit in kind, it is based on the date [the recipient received the benefit].

4. Direct and Indirect Transfers of Value

For direct transfers of value, the recipient is the person or entity holding the bank account receiving the money and beneficiary of the transfer of value.

Kyowa Kirin Ltd and Kyowa Kirin International also provides indirect transfers of value.

In the case of payments that are made through Clinical Research Organisations, these are included under Research and Development and reported in the aggregate.

Where a third party has been appointed by an HCO to manage an event, and where the HCO benefits from the transfer of value, these transfers of value are disclosed against the HCO.

Where third parties are appointed by KKI to make travel and accommodation arrangements for HCPs, the transfers of value are reported against the HCP who received the benefit.

5. Cross-border activities

KKI makes best efforts to capture and report all transfers of value to HCPs and HCOs with primary practice in a country with EFPIA Disclosure Code or other transparency reporting requirements. The country of disclosure is based on the HCP's principal practice or the HCO's country of registration.

6. Consent

In UK & Ireland HCOs are reported without the need for consent as they are legal entities.

For transfers of value in 2021 HCP's consent is collected on an annual basis at the time of first contracting. If consent is not provided, the transfer of value that they have received is included in the aggregate amount. If no response is received a "no" response is assumed, and the data is also reported in the aggregate.

HCPs have the right to amend their consent status at any time by contacting kki_compliance_northerncluster@kyowakirin.com.

7. Disclosure

Our report of in 2021 is published at <https://international.kyowa-kirin.com/uk/transparency/> in English.

The currency used for disclosure is Sterling GBP in the UK and Euros in Ireland.

In the case that payments are made in a currency other than where the payment will be reported the payment amount is converted to the reporting currency using the daily exchange rate between the two currencies on the day of payment.

All Transfers of Value include VAT where applicable.

Any questions regarding this disclosure should be directed to David Eves, Compliance Director kki_compliance_northerncluster@kyowakirin.com